Bracco
Bracco is an Italian family-owned life-sciences group focused on diagnostic imaging, including contrast agents, medical technologies, and related health services.
Last updated September 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Bracco is an Italian life-sciences company and the group brand of Bracco Group. The company traces its foundation to 1927, when Elio Bracco incorporated a small pharmaceutical-trading business in Milan. Bracco describes itself as a family-owned company and a world leader in imaging diagnostics. Its stated purpose is to improve people’s lives by shaping the future of prevention and precision imaging. The group’s central area is diagnostic imaging. It develops, manufactures, and markets contrast agents and medical devices, along with more advanced solutions intended to support diagnostic-imaging professionals and patients. Bracco says its contrast agents are routinely used with conventional X-ray imaging, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and nuclear medicine. Its business areas are imaging agents, medical technologies, and health services. Bracco reports that its contrast media are sold in more than 100 countries, through a combination of direct operations, branches, joint ventures, and licensing and distribution agreements. It identifies North America, China, Europe, and Japan among its important geographical markets. Its publicly presented portfolio and activities include contrast-imaging solutions, VueJect ultrasound contrast delivery technology, and research-use BubbleGen cell-selection products for cell-therapy research. The company has also announced regulatory authorizations for VueJect in the United States and Canada, approval in Canada for gadopiclenol injection, and the European Union launch of AiMIFY. Bracco presents research, innovation, sustainability, and patient-focused outcomes as recurring priorities. It describes sustainability as central to its growth and reports receiving an EcoVadis Platinum Medal for a second consecutive year. The company remains active and presents itself as a global imaging-diagnostics business rooted in its Milan origins and family ownership.
History
Bracco’s corporate history begins in Milan in 1927. According to the company’s account, Elio Bracco signed the notarial deed incorporating the business shortly before 1 July of that year, and a small pharmaceutical-trading company opened an office at Piazzale Susa in Milan on 1 July. The undertaking that began as a trading business developed into the Bracco Group. A major early phase of development came under Elio’s son, Fulvio Bracco, who joined the firm after graduating from the University of Pavia. In the 1950s, Fulvio concentrated research on the chemistry of iodine and its use in diagnostic imaging. The company’s account describes this as a niche field at the time and identifies that research direction as a foundation for Bracco’s subsequent development in imaging diagnostics. The company also highlights a post-war industrial milestone: in 1949, Fulvio established a new factory in Milan’s Lambrate district and placed research and innovation at the center of its future. Bracco’s official history presents this investment and its later iodine-related research as important stages in the transformation from a pharmaceutical-trading concern into a specialist in diagnostic imaging. In its present-day description, Bracco is a multinational life-sciences company and a family-owned global player in imaging diagnostics. Its work spans the development, manufacture, and marketing of contrast agents, medical devices, and other solutions for diagnostic imaging. The company identifies imaging agents, medical technologies, and health services as its business areas. It says its contrast media are used across conventional X-ray imaging, CT, MRI, ultrasound, and nuclear medicine, and that they reach more than 100 countries through direct and indirect commercial arrangements. Recent corporate communications emphasize continued development of imaging products and technologies, regulatory progress, international launches, sustainability, and partnerships. Announcements on the company homepage include U.S. and Canadian authorizations for VueJect, Canadian approval for gadopiclenol injection, the European Union launch of AiMIFY, and a strategic alliance between Bracco Imaging and NYU Langone Health. The available corporate history and homepage evidence establish the company’s origins, family-business identity, research orientation, current business scope, and selected recent announcements; they do not provide a dated account of every intervening expansion or product launch.
Products and positioning
A family-owned global life-sciences company specializing in diagnostic imaging, contrast agents, medical technologies, and solutions intended to support prevention and precision imaging.
VueJect
A dedicated ultrasound contrast delivery system; the company reports U.S. FDA 510(k) clearance and Health Canada authorization.
Gadopiclenol injection
An injectable imaging product for which Bracco announced Health Canada approval.
AiMIFY
A Bracco offering whose European Union launch was announced by the company.
BubbleGen CD3+ Cell Selection Kit
A ready-to-use research-use-only product for enrichment of CD3+ T cells using Bracco's microbubble technology; not for use in humans.
BubbleGen Cell Separators
Research-use-only cell separators intended for use with BubbleGen cell-selection kits.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/bracco · Editorial policy · How profiles are compiled